Bhavsar Dhiraj, Subramanian Krishnakumar, Sethuraman Swaminathan, Krishnan Uma Maheswari
a School of Chemical & Biotechnology, Centre for Nanotechnology & Advanced Biomaterials, Sastra University , Thanjavur , Tamil Nadu , India and.
b L&T Ophthalmic Pathology Department , Vision Research Foundation , Sankara Nethralaya , Chennai , Tamil Nadu , India.
Drug Deliv. 2016 Sep;23(7):2488-2496. doi: 10.3109/10717544.2015.1016193. Epub 2015 Mar 11.
Nano-delivery systems have significantly evolved over the last decade for the treatment of cancer by enabling site-specific delivery and improved bioavailability. The widely investigated nanoparticle systems are biodegradable polyesters, dendrimers, liposomes, mesoporous silica and gold nanoparticles. These particles when conjugated with different targeting motifs enhance the therapeutic efficiency of the drug molecules and biocompatibility. However, the application of such systems towards the treatment of retinoblastoma (RB), a rapidly spreading childhood eye cancer, still remains in its infancy. Nanoparticle-based systems that have been investigated for RB therapy have displayed improved drug delivery to the most restricted posterior segment of the eyes and have increased intra-vitreal half-life of the chemotherapy agents highlighting its potential in treatment of this form of cancer. This review focuses on the challenges involved in the treatment of RB and highlights the attempts made to develop nano-dimensional systems for the treatment of RB.
在过去十年中，纳米递送系统在癌症治疗方面取得了显著进展，能够实现药物的位点特异性递送并提高生物利用度。广泛研究的纳米颗粒系统包括可生物降解聚酯、树枝状大分子、脂质体、介孔二氧化硅和金纳米颗粒。这些颗粒与不同的靶向基序结合时，可提高药物分子的治疗效率和生物相容性。然而，此类系统在治疗视网膜母细胞瘤（RB）（一种迅速蔓延的儿童眼部癌症）方面的应用仍处于起步阶段。已针对RB治疗进行研究的基于纳米颗粒的系统显示出，药物向眼部最受限的后段递送得到改善，化疗药物的玻璃体内半衰期延长，凸显了其在治疗这种癌症方面的潜力。本综述重点关注RB治疗中涉及的挑战，并强调为开发用于治疗RB的纳米尺寸系统所做的努力。
